Paclitaxel.

DRUG2 trials

Conditions

Acute T Cell Leukemia LymphomaBone CancerBone MetastasesBone NeoplasmBreast NeoplasmsCancerExtrapulmonary Neuroendocrine Carcinoma (EP-NEC)Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Phase 1

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

RecruitingNCT05652686

Phanes TherapeuticsExtrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Large Cell Neuroendocrine Cancer (LCNEC) +3

Start: 2023-09-05End: 2028-08-31Target: 203Updated: 2025-09-23

Phase 2

9-ING-41 in Patients With Advanced Cancers

Active, not recruitingNCT03678883

Actuate Therapeutics Inc.Acute T Cell Leukemia Lymphoma, Bone Cancer, Bone Metastases +22

Start: 2019-01-04End: 2026-06-01Target: 350Updated: 2026-04-03

Journal of Clinical Oncology2026-01-10

Mutational analysis and identification of potential biomarkers in patients with metastatic pancreatic cancer treated with the combination of the GSK-3 inhibitor elraglusib and gemcitabine/nab-paclitaxel in the 1801 Part 3B phase 2 study.

Journal of Clinical Oncology2026-01-10

Preliminary results from the randomized phase 2 study (1801 part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).

Journal of Clinical Oncology2025-05-284 citations

An open-label, multicenter, phase 1/2 study of peluntamig (PT217), an anti-DLL3/anti-CD47 bispecific antibody, in patients with DLL3-expressing cancers such as SCLC, LCNEC and EP-NEC (SKYBRIDGE study).

Journal of Clinical Oncology2025-05-281 citations

Machine learning and statistical prediction of overall survival (OS) from pre-dose plasma biomarkers in a randomized phase 2 trial (1801 Part 3B) of the GSK-3 inhibitor elraglusib in metastatic pancreatic ductal adenocarcinoma (mPDAC): Application toward patient enrichment.

Journal of Clinical Oncology2025-05-28

Correlation of therapy-induced neutropenia with survival in patients with metastatic pancreatic cancer treated with GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.

Journal of Clinical Oncology2024-06-013 citations

Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.

Journal of Clinical Oncology2024-06-012 citations

Mutational analysis of cfDNA to identify predictive biomarkers in previously untreated patients with metastatic pancreatic cancer receiving the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.

Journal of Clinical Oncology2024-06-011 citations

Abstract 6426: Identification of potential immune biomarkers for GSK-3 inhibitor elraglusib (9-ING-41) in patients with relapsed/refractory metastatic cancer

Cancer Research2024-03-221 citations

Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).

Journal of Clinical Oncology2023-06-013 citations

In silico approaches to patient selection: Credentialing elraglusib as a novel treatment in metastatic melanoma resistant to checkpoint inhibitors.

Journal of Clinical Oncology2023-06-012 citations

Plasma cytokine profiles and survival outcomes in the 1801 phase 1/2 clinical trial of 9-ING-41 (elraglusib) in patients with advanced cancer.

Journal of Clinical Oncology2023-06-01

GSK-3 inhibitor elraglusib (9-ING-41) to enhance tumor-infiltrating immune cell activation in tumor biopsies and synergize with anti-PD-L1 in a murine model of colorectal cancer.

Journal of Clinical Oncology2023-06-01

Abstract CT222: Multimodal mechanism of action of the GSK-3 inhibitor 9-ING-41 (elraglusib) includes an immunomodulatory component: preliminary results from the 1801 phase 1/2 trial

Cancer Research2023-04-14

Abstract 5636: Multiplex digital spatial profiling (DSP) of proteins in the tumor microenvironment in response to GSK-3 inhibition by 9-ING-41 (elraglusib) correlates with novel immunostimulatory effects observed <i>in vivo</i>

Cancer Research2023-04-04

Abstract 5355: Elraglusib response prediction and mechanistic discovery using iterative machine learning

Cancer Research2023-04-04

Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8<sup>+</sup> T cell cytolytic killing of melanoma cells.

2022-09-1436 citations

Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma

Cancer Biology & Therapy2022-07-0922 citations

Phase 2 study of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, with gemcitabine/nab-paclitaxel (GnP) in first-line advanced pancreatic ductal adenocarcinoma (PDAC).

Journal of Clinical Oncology2022-01-19

Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies

Neuro-Oncology Advances2022-01-016 citations

8 more papers not shown

Paclitaxel.

Sponsors

Conditions

Phase 1

Phase 2

Related Papers